Expert Review of Anticancer Therapy最新文献_第9页

Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer. 2024 年 ASCO 泌尿生殖系统专题讨论会要点：聚焦尿路上皮癌和前列腺癌。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1080/14737140.2024.2370384

Alessandro Strusi, Giada Pinterpe, Chiara Ciccarese, Romina Rose Pedone, Michele Sarcina, Valeria Sardaro, Rachele Belletto, Angelo Totaro, Marco Racioppi, Rossana Berardi, Giampaolo Tortora, Roberto Iacovelli

引用次数: 0

Risks and benefits of sentinel lymph node evaluation in the management of endometrial intraepithelial neoplasia. 前哨淋巴结评估在子宫内膜上皮内瘤治疗中的风险和益处。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-18 DOI: 10.1080/14737140.2024.2372329

Lauren M Lim, Hadi Erfani, Katelyn B Furey, Koji Matsuo, X Mona Guo

{"title":"Risks and benefits of sentinel lymph node evaluation in the management of endometrial intraepithelial neoplasia.","authors":"Lauren M Lim, Hadi Erfani, Katelyn B Furey, Koji Matsuo, X Mona Guo","doi":"10.1080/14737140.2024.2372329","DOIUrl":"10.1080/14737140.2024.2372329","url":null,"abstract":"Introduction: Endometroid intraepithelial neoplasia (EIN) is a premalignant lesion to endometrial cancer. Increasing number of gynecologic oncologists are performing sentinel lymph node (SLN) evaluation during hysterectomy for EIN to ensure complete staging if there is cancer on the final specimen. However, there are no clear guidelines and the benefits and risks to performing SLN evaluation for EIN patients are unclear.Areas covered: This narrative review examines the advantages and disadvantages of SLN evaluation for EIN patients and provides an algorithm to assist clinicians in selectively applying the procedure for maximal patient benefit. Relevant articles up to March 2024 were obtained from a PubMed search on SLN use with endometrial pathology.Expert opinion: Sentinel lymph node evaluation for patients with EIN is safe, feasible, and particularly important for the approximately 10% of patients with high-risk endometrial carcinoma on final pathology. However, as most diagnosed carcinomas are low-risk, SLN evaluation would have limited oncologic benefit. While SLN assessment may overtreat most patients with EIN, a significant minority of patients will be improperly staged. We propose an algorithm highlighting the importance of maximal preoperative endometrial sampling and stratifying patients via risk factors to selectively identify those who would benefit most from SLN evaluation.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"745-753"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals. 用于癌症治疗的多靶点多聚芳香醚疗法。理论概念和建议。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-08 DOI: 10.1080/14737140.2024.2372336

Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui

{"title":"Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals.","authors":"Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui","doi":"10.1080/14737140.2024.2372336","DOIUrl":"10.1080/14737140.2024.2372336","url":null,"abstract":"Introduction: The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is 2.8 months. Targeted therapy is based on the somatic mutation theory, which has some paradoxes and limitations. While efforts of targeted therapy must continue, we must study newer approaches that could advance therapy and affordability for patients.Areas covered: This work briefly overviews how cancer therapy has evolved from cytotoxic chemotherapy to current molecular-targeted therapy. The limitations of the one-target, one-drug approach considering cancer as a robust system and the basis for multitargeting approach with polypharmacotherapy using repurposing drugs.Expert opinion: Multitargeted polypharmacotherapy for cancer with repurposed drugs should be systematically investigated in preclinical and clinical studies. Remarkably, most of these proposed drugs already have a long history in the clinical setting, and their safety is known. In principle, the risk of their simultaneous administration should not be greater than that of a first-in-human phase I study as long as the protocol is developed with strict vigilance to detect early possible side effects from their potential interactions. Research on cancer therapy should go beyond the prevailing paradigm targeted therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"665-677"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 在监测早期和晚期乳腺癌方面，ctDNA 是否已准备好超越成像技术？

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-01 DOI: 10.1080/14737140.2024.2362173

Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, Elisabetta Molteni, Linda Cucciniello, Lucia Da Ros, Buriolla Silvia, Lorenzo Cereser, Rossana Roncato, Lorenzo Gerratana, Fabio Puglisi

{"title":"Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?","authors":"Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, Elisabetta Molteni, Linda Cucciniello, Lucia Da Ros, Buriolla Silvia, Lorenzo Cereser, Rossana Roncato, Lorenzo Gerratana, Fabio Puglisi","doi":"10.1080/14737140.2024.2362173","DOIUrl":"10.1080/14737140.2024.2362173","url":null,"abstract":"Introduction: Circulating tumor DNA (ctDNA) and radiological imaging are increasingly recognized as crucial elements in breast cancer management. While radiology remains the cornerstone for screening and monitoring, ctDNA holds distinctive advantages in anticipating diagnosis, recurrence, or progression, providing concurrent biological insights complementary to imaging results.Areas covered: This review delves into the current evidence on the synergistic relationship between ctDNA and imaging in breast cancer. It presents data on the clinical validity and utility of ctDNA in both early and advanced settings, providing insights into emerging liquid biopsy techniques like epigenetics and fragmentomics. Simultaneously, it explores the present and future landscape of imaging methodologies, particularly focusing on radiomics.Expert opinion: Numerous are the current technical, strategic, and economic challenges preventing the clinical integration of ctDNA analysis in the breast cancer monitoring. Understanding these complexities and devising targeted strategies is pivotal to effectively embedding this methodology into personalized patient care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"679-691"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials. 晚期表皮生长因子受体突变 NSCLC 一线联合 EGFR-TKI + 化疗与单用 EGFR-TKI：随机 III 期试验荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-03 DOI: 10.1080/14737140.2024.2362889

Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaïd

{"title":"First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.","authors":"Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaïd","doi":"10.1080/14737140.2024.2362889","DOIUrl":"10.1080/14737140.2024.2362889","url":null,"abstract":"Introduction: A tyrosine-kinase inhibitor (TKI) is indicated as a first-line treatment for patients with non-small-cell lung cancer (NSCLC) harboring an epidermal growth-factor - receptor (EGFR) mutation. Chemotherapy (ChT) given in combination with an EGFR-TKI in this setting is of interest.Methods: We conducted a meta-analysis of phase III randomized trials comparing EGFR-TKI + ChT vs. EGFR-TKI alone as first-line therapy for advanced NSCLC harboring an activating EGFR mutation.Results: Three studies evaluated gefitinib + ChT (NEJ009, GAP-Brain, and Noronha et al.) and another evaluated osimertinib + ChT (FLAURA-2). Those four eligible studies included 1413 patients with non-squamous NSCLCs, 826 (58%) with an exon-19 deletion (ex19del) and 541 (38%) with EGFRL858R. The EGFR-TKI + ChT combination was significantly associated with prolonged PFS (hazard ratio [HR]: 0.52 [95% confidence interval (CI): 0.45-0.59]; p < 0.0001) and OS (HR: 0.69 [0.52-0.93]; p = 0.01). PFS was particularly improved for patients with brain metastases (HR: 0.41[0.33-0.51]; p < 0.00001).Conclusions: For patients with untreated, advanced, EGFR-mutated NSCLCs, the EGFR-TKI + ChT combination, compared to EGFR-TKI alone, was associated with significantly prolonged PFS and OS. However, further studies are needed to identify which patients will benefit the most from the combination.Registration: PROSPERO CRD42024508055.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"775-780"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nomogram and calculator for predicting the prognosis of patients with giant hepatocellular carcinoma. 预测巨大肝细胞癌患者预后的提名图和计算器。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-17 DOI: 10.1080/14737140.2024.2369129

Wanjin Chen, Shengtao Cheng

{"title":"Nomogram and calculator for predicting the prognosis of patients with giant hepatocellular carcinoma.","authors":"Wanjin Chen, Shengtao Cheng","doi":"10.1080/14737140.2024.2369129","DOIUrl":"10.1080/14737140.2024.2369129","url":null,"abstract":"Objectives: This study aimed to explore the factors affecting the overall survival (OS) of giant hepatocellular carcinoma (G-HCC) patients and establish a nomogram and an Internet-based OS calculator for evaluating the OS of G-HCC patients.Research design and methods: A total of 2445 G-HCC patients were searched in the SEER database. The independent variables affecting OS of G-HCC patients were determined by univariate and multivariate analyses, and a nomogram and Internet-based OS calculator were established. The accuracy of the nomogram was evaluated by the C-index, the AUC curve, and calibration curve.Results: Grade, surgery, radiotherapy, chemotherapy, T-staging, M-staging, AFP, and fibrosis were identified as independent variables affecting OS. These variables were included in the nomogram model and Internet-based OS calculator to evaluate OS in G-HCC patients. The C-indices and AUC of the nomogram are better than AJCC-staging system. Similarly, the calibration curves revealed that the actual survival was consistent with nomogram-based survival.Conclusion: The nomogram and Internet-based OS calculator are superior to the traditional AJCC-staging system in the reliability and convenience of prognosis assessment for G-HCC patients, which is more conducive for clinicians to predict the survival of G-HCC patients and make the best treatment strategy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"781-788"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma. 治疗复发性/难治性大 B 细胞淋巴瘤的双特异性抗体。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-03 DOI: 10.1080/14737140.2024.2362186

Gulrayz Ahmed, Fateeha Furqan, Elham Nasrollahi, Mehdi Hamadani

{"title":"Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.","authors":"Gulrayz Ahmed, Fateeha Furqan, Elham Nasrollahi, Mehdi Hamadani","doi":"10.1080/14737140.2024.2362186","DOIUrl":"10.1080/14737140.2024.2362186","url":null,"abstract":"Introduction: The management of relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) has witnessed dramatic changes in the recent past. Despite the availability of multiple novel immunotherapies in R/R setting, there remains an unmet need for off-the-shelf therapies, particularly in patients with primary refractory, multiply relapsed disease or those experiencing cellular immunotherapy failure. To harness the power of the T-cell mediated immunity, a novel class of drugs called bispecific antibodies (BsAbs) have been developed. These BsAbs are currently under investigation both in frontline and R/R setting and hold the potential to revolutionize the management of LBCL.Areas covered: This review article summarizes the currently available BsAbs, their mode of action, efficacy, and safety data for untreated and R/R LBCL. In addition, the role of these BsAbs in combination with currently available chemoimmunotherapy regimens is also discussed.Expert opinion: Two BsAbs have secured FDA approval for R/R LBCL, with expected approval of more BsAbs (including in earlier treatment lines). These drugs provide a highly efficacious and relatively safe treatment option for patients with highly pretreated disease including relapse after cellular immunotherapies. In addition, these BsAbs provide a platform for chemotherapy-free regimen for older/frail patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"705-715"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review. 转移性肾细胞癌的多学科全身和局部疗法：综述。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-03 DOI: 10.1080/14737140.2024.2362192

Martin Zarba, Ryo Fujiwara, Takeshi Yuasa, Fumitaka Koga, Daniel Y C Heng, Kosuke Takemura

{"title":"Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review.","authors":"Martin Zarba, Ryo Fujiwara, Takeshi Yuasa, Fumitaka Koga, Daniel Y C Heng, Kosuke Takemura","doi":"10.1080/14737140.2024.2362192","DOIUrl":"10.1080/14737140.2024.2362192","url":null,"abstract":"Introduction: Systemic and local therapies for patients with metastatic renal cell carcinoma (mRCC) are often challenging despite the evolution of multimodal cancer therapies in the last decade. In this review, we will focus on recent multidisciplinary approaches for patients with mRCC.Areas covered: Systemic therapies for patients with mRCC have been garnering attention particularly after the approval of immuno-oncology (IO) agents, including anti-programmed death 1/programmed death-ligand 1. IO combinations have significantly prolonged overall survival in patients with mRCC in the first-line setting. Regarding local therapies, cytoreductive nephrectomy (CN) has become less common in the post-Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial era, even though CN may still benefit selected patients with mRCC. In addition, metastasis-directed local therapies, namely metastasectomy or stereotactic radiotherapy, particularly for oligo-metastatic lesions or brain metastases, may have a prognostic impact. Several ablative techniques are also evolving while maintaining high local control rates with acceptable safety.Expert opinion: Multimodal cancer therapies are essential for conquering complex cases of mRCC. Modern systemic therapies including IO-based combination therapy as well as local therapies including CN, metastasectomy, stereotactic radiotherapy, and ablative techniques appear to improve oncologic outcomes of patients with mRCC, although appropriate patient selection is indispensable.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"693-703"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment options in the advanced and recurrent setting for endometrial cancer: an update. 子宫内膜癌晚期和复发的治疗方案：最新进展。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-24 DOI: 10.1080/14737140.2024.2370377

Alex Andrea Francoeur, Virginia Fontenont, Krishnansu Sujata Tewari

{"title":"Treatment options in the advanced and recurrent setting for endometrial cancer: an update.","authors":"Alex Andrea Francoeur, Virginia Fontenont, Krishnansu Sujata Tewari","doi":"10.1080/14737140.2024.2370377","DOIUrl":"10.1080/14737140.2024.2370377","url":null,"abstract":"Introduction: Uterine cancer is the most common gynecologic malignancy in women and is projected to surpass ovarian cancer as the deadliest gynecologic malignancy in the United States in 2024. Additionally, rates of advanced and high-risk uterine cancer have been on the rise in the United States, demonstrating a need for innovation in treatment options. There have been multiple recent trials investigating the incorporation of novel agents in the treatment of advanced and recurrent endometrial cancer.Areas covered: This article will discuss the current landscape of the treatment of advanced and recurrent endometrial cancer, focusing on recent phase III trials published or presented on with the incorporation of immunotherapy and other novel therapeutics while also reviewing promising phase I and II trials in the field. Clinical trials were identified via clinicaltrials.gov and a PubMed literature search was performed (initially February 2024, updated May 2024).Expert opinion: The treatment field is promising for patients as many of these trials appear to offer progression free and overall survival benefits in a disease with a historically poor prognosis. Molecular profiling of endometrial cancer will be the backbone of treatment paradigms in the future.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"731-744"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of planetary health in urologic oncology. 地球健康在泌尿肿瘤学中的作用。

IF 3.3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-07-01 Epub Date: 2024-05-11 DOI: 10.1080/14737140.2024.2350631

Laura Lawaczeck, Julia Rudolph, Valentina Norz, Igor Tsaur, Steffen Rausch

{"title":"The role of planetary health in urologic oncology.","authors":"Laura Lawaczeck, Julia Rudolph, Valentina Norz, Igor Tsaur, Steffen Rausch","doi":"10.1080/14737140.2024.2350631","DOIUrl":"10.1080/14737140.2024.2350631","url":null,"abstract":"Introduction: Climate change and global warming are an omnipresent topic in our daily lives. Planetary health and oncology represent two critical domains within the broader spectrum of healthcare, each addressing distinct yet interconnected aspects of human well-being. We are encouraged to do our part in saving our planet. This should include the decisions we make in our professional life, especially in uro-oncology, as the healthcare sector significantly contributes to environmental pollution.Areas covered: There are many aspects that can be addressed in the healthcare sector in general, as there are structural problems in terms of energy consumption, water waste, therapeutic techniques, transportation and drug manufacturing, as well as in uro-oncology specific areas. For example, the use of different surgical techniques, forms of anesthesia and the use of disposable or reusable instruments, each has a different impact on our environment. The literature search was carried out using PubMed, a medical database.Expert opinion: We are used to making decisions based on the best outcome for patients without considering the impact that each decision can have on the environment. In the present article, we outline options and choices for a more climate-friendly approach in urologic oncology.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"513-523"},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0